Riskpilot← Back to searchSign inGet full accessINIFY Laboratories AB
ABActiveOrg 5593454431Scheeles Väg 3Activities of head offices · NACE 7010Est. 202120 employees
Revenue 2024
SEK 2,4M
+157% vs 2023
EBITDA margin
-2049.6%
-2% vs 2023
Equity ratio
78.8%
Financial strength
Net profit 2024
SEK -53,2M
0% vs 2023
| Revenue | SEK 2,4M | +157% |
| EBITDA | SEK -49,9M | -2% |
| Net profit | SEK -53,2M | +0% |
| Total assets | SEK 40,4M | -56% |
| Equity | SEK 31,9M | -63% |
| Employees | 20 | — |
Legal name
INIFY Laboratories AB
Org number
5593454431
Legal form
Aktiebolag
NACE code
7010 · Activities of head offices
Founded
10 november 2021
Share capital
SEK 2 923 000
Employees
20 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhet skall vara att, direkt eller indirekt genom dotter- eller intressebolag, bedriva forskning och utveckling av metoder och system för cancerdiagnostik, utveckling och försäljning av sjukvårdstjänster med särskild inriktning på laboratoriemedicinsk verksamhet, äga och förvalta fast och lös egendom, däribland aktier och andelar i andra företag samt idka annan därmed förenlig verksamhet.
Address
Scheeles Väg 3
Email
info@inify.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 946 | 2 435 |
| Staff expenses | — | — | — |
| EBITDA | −42 274 | −49 106 | −49 907 |
| Depreciation & amort. | −2 345 | −4 333 | −4 561 |
| EBIT | −44 619 | −53 439 | −54 468 |
| Net financials | 462 | −2 208 | 1 299 |
| Profit before tax | −44 157 | −53 326 | −53 168 |
| Tax | −0 | −0 | −0 |
| Net profit | −44 157 | −53 326 | −53 168 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 152 128 | 92 412 | 40 435 |
| Equity | 138 372 | 85 046 | 31 877 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 13 756 | 7 366 | 8 557 |
| Total debt | 13 756 | 7 366 | 8 557 |
EBITDA margin
-2049.6%
This company
15.8%
Market median
-13072% vs market
20222024
Equity ratio
78.8%
This company
38.2%
Market median
+106% vs market
20222024
Return on equity
-166.8%
This company
18.4%
Market median
-1007% vs market
20222024
Net profit margin
-2183.5%
This company
8.1%
Market median
-27057% vs market
20222024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20222024
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JK Chief Auditor | Chief Auditor | 2022 |
UF Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (3) | ||
HJ Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
ME Audit | Audit | 2021 – 2022 |
AB Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (11) | ||
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Chairman | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 60% | 60% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GALLIVANT S. .R.L.
INIFY Laboratories AB (this company)Board members of INIFY Laboratories AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Jarl Rutger Arnhult | Chief Executive Officer | 0 companies |
| John Kjell Joakim Söderin | Chief Auditor | 0 companies |
| Ulf Fredrik Palm | Chief Executive Officer | 0 companies |
| Mattias Eriksson | Audit | 0 companies |
| Andreas Bo Henrik Troberg | Chief Auditor | 0 companies |
| Bo Daniel Falk | Board of Directors | 0 companies |
| Viktor Elias Bergman Gullmark | Deputy Board Member | 0 companies |
| Lars Olof Sandén | Chairman | 0 companies |
| Emma Maria Birgitta Wik | Deputy Board Member | 0 companies |
| Anna Matilda Sjödin | Deputy Board Member | 0 companies |
| Lars Anders Larsson | Chairman | 0 companies |
| Emelie Sofia Bergh | Deputy Board Member | 0 companies |
| Anna Carolina Maria Bjarnhagen | Deputy Board Member | 0 companies |
| Magne Jordanger | Board of Directors | 0 companies |
| Rolf Stefan Janse | Deputy Board Member | 0 companies |
| Mari Sinikka Kovaniemi Feldt | Deputy Board Member | 0 companies |
| Sven Christian Günther-Hanssen | Board of Directors | 0 companies |
| Olina Kristina Maria Wåhlstedt | Deputy Board Member | 0 companies |
| Knut Martin Henschen Ingvar | Board of Directors | 0 companies |